FDA sets meeting to discuss improving benefit-risk assessments

FDA will seek input at a May 16 public hearing on ways to make benefit-risk assessments publicly accessible, which may include publishing benefit-risk

Read the full 234 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE